Zejula Leads to Fewer Side Effects Than Previously Reported, Real-world Study Suggests

Zejula Leads to Fewer Side Effects Than Previously Reported, Real-world Study Suggests
Ovarian cancer patients who receive Zejula (niraparib) after responding to platinum-based chemotherapy experience fewer adverse effects in a real-world setting than was reported in a Phase 3 clinical trial, a study found. However, the lower rate of side effects “may be due to the higher dosing in the trial study,” researchers wrote. The study, “Real world

Knowledge is power when living with ovarian cancer.

Get access to the web’s leading Ovarian Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *